Chlorpromazine for psychosis induced aggression or agitation

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Gul, Muhammad ^a   Ahmed, Uzair ^a   Adams, Clive E ^b  

^a RAMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CHLORPROMAZINE; NEUROLEPTIC AGENT;

AGGRESSION; AGITATION; BEHAVIOR; CLINICAL TRIAL; DEATH; ECONOMIC ASPECT; HUMAN; MENTAL HEALTH; PATIENT SATISFACTION; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SLEEP; SUICIDE; SYSTEMATIC REVIEW;

EID: 55049090926     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007445     Document Type: Review

References (28)

1. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: OLZ020600]
2. Bazier 2007 Bazier S. Psychotropic drug directory. Stockport, UK: Health Comm UK Limited, March 2007.
3. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
4. BNF 2008 British National Formulary. British National Formulary. 55. NHS, London: Pharmaceutical Press, March 2008.
5. CIA 2008 Central Intelligence Agency. The World Factbook. https://www.cia.gov/library/publications/theworld-factbook/ [Accessed 21st July 2008] 2008.
6. Cunnane 1994 Cunnane JG. Drug management of disturbed behaviour by psychiatrists. Psychiatric Bulletin 1994;18:138-9. [PUBMED: 12383353]
7. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
8. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
9. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
10. Elbourne 2002 Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
11. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83 876-83.
12. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
13. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for systematic reviews of interventions 4.2.5. Cochrane Handbook for systematic reviews of interventions 4.2.5. Chichester, UK: John Wiley and Sons, Ltd., 2005.
14. Kalyana 2006 Kalyana Z, Bezchlibnky-Butler J, Jefferies J. Clinical Handbook of Psychotropic Drugs. 16th Edition. New York, London: Hogrefe & Huber, 2006.
15. Keltner 2001 Keltner NL, Folke DG. Psychotropic Drugs. 3rd Edition. St Louis, Missouri: Mosby, 2001.
16. Lopez-Munez 2005 Lopez-Munez F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry 2005;17(3):113-35.
17. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
18. NHS 2008 NHS Business Services Authority. Prescription Pricing Division. http://www.ppa.org.uk/ppa/ppa_main.htm[Accessed 21st July 2008] 2008.
19. NICE 2005 National Collaborating Centre for Nursing and Supportive Care. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. http://www.nice.org.uk/Guidance/ CG25/NiceGuidance/pdf/English [Accessed August 2008] 2005.
20. Sartorius 1972 Sartorius N, Shapiro R, Kimura M, Barrett K. WHO international pilot study of schizophrenia. Psychological Medicine 1972;2(4):422-5. [PUBMED: 4656537]
21. Seaman 2004 Seaman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse [online] 12 Oct 2004;1(2): 133-52.
22. Shah 2000 Shah A, Jenkins R. Mental health economic studies from developing countries reviewed in the context of those from developed countries. Acta Psychiatrica Scandinavica 2000;101(2):87-103.
23. Swanson 1990 Swanson J, Hozler C, Ganju VR. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hospital and Community Psychiatry 1990;41:761-70.
24. Tardiff 1982 Tardiff K, Sweillam A. Assaultive behavior among chronic inpatients. American Journal of Psychiatry 1982;139:212-5.
25. Turner 2007 Turner T. Chlorpromazine: unlocking psychosis. BMJ 2007;334(Suppl. 1):s7. [PUBMED: 17204765]
26. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
27. WHO 2007 World Health Organisation. WHO Essential medicines list. WHO essential medicines list. 15th Edition. Geneva: World Health Organization, March 2007.
28. WPA 2003 World Psychiatric Association. The usefulness and use of second-generation antipsychotic medications (An update of the Review of Evidence and Recommendations by a Task Force of the World Psychiatric Association). http://www.peoplewho.org/documents/WPA2ndgenantipDOC.doc [Accessed 21st July 2008]. Yokohama, Japan, 2003.